[New perspectives in the pharmacological treatment of glaucoma].
Open angle glaucoma is an optic neuropathy, the etiology of which is still unknown and which has not yet satisfactory therapy. Intraocular hypertension due to a decrease in trabecular out flow facility, is a risk factor. The side effects caused by ocular hypotensive treatments justify the search for better-tolerated drugs. A survey of the new approaches is reported: carbonic anhydrase inhibition, renin-angiotensin system inhibition, glucocorticoid antagonism, the use of prostaglandins etc. are evoked, as well as other more speculative ways: antioxidant treatments. Glaucoma which is characterized by ganglion cell degeneration probably related to a vascular defect, deserves to be studied from this point of view. Recent data on vascular and haemorheological abnormalities and the possible involvement of excitotoxic neurotransmitters in pathological process open a novel way for really innovative pharmacological research.
Bonne
C
C
Laboratoire de Physiologie Cellulaire, Université Montpellier I, Faculté de Pharmacie.
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D018056:Hemorheology; D006801:Humans; D009410:Nerve Degeneration; D009798:Ocular Hypertension / Q000150:complications / Q000188:drug therapy; D009900:Optic Nerve / Q000187:drug effects; D011453:Prostaglandins / Q000627:therapeutic use; D014652:Vascular Diseases / Q000150:complications / Q000188:drug therapy
D000975:Antioxidants; D011453:Prostaglandins
Nouvelles perspectives dans le traitement pharmacologique du glaucome.